Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chronic Pain | 18 | 2022 | 110 | 4.020 |
Why?
|
| Nicotine | 15 | 2023 | 350 | 2.640 |
Why?
|
| Opioid-Related Disorders | 15 | 2022 | 298 | 2.620 |
Why?
|
| Smoking | 20 | 2022 | 1452 | 2.330 |
Why?
|
| Smoking Cessation | 18 | 2022 | 1034 | 2.170 |
Why?
|
| Prescription Drug Misuse | 6 | 2018 | 35 | 2.030 |
Why?
|
| Tobacco Use Disorder | 10 | 2023 | 432 | 1.960 |
Why?
|
| Frontal Lobe | 6 | 2019 | 156 | 1.910 |
Why?
|
| Analgesics, Opioid | 16 | 2022 | 498 | 1.820 |
Why?
|
| Mindfulness | 8 | 2022 | 41 | 1.570 |
Why?
|
| Emotions | 7 | 2022 | 244 | 1.500 |
Why?
|
| Affect | 8 | 2019 | 218 | 1.360 |
Why?
|
| Corpus Striatum | 3 | 2019 | 279 | 1.330 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2023 | 2223 | 1.280 |
Why?
|
| Cues | 13 | 2022 | 654 | 1.200 |
Why?
|
| Depression | 5 | 2016 | 943 | 1.020 |
Why?
|
| Craving | 7 | 2022 | 200 | 0.990 |
Why?
|
| Nerve Net | 4 | 2017 | 181 | 0.900 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2015 | 435 | 0.880 |
Why?
|
| Reward | 8 | 2019 | 201 | 0.770 |
Why?
|
| Adult | 40 | 2023 | 21403 | 0.750 |
Why?
|
| Attention | 6 | 2015 | 225 | 0.740 |
Why?
|
| Psychomotor Performance | 6 | 2019 | 213 | 0.730 |
Why?
|
| Behavior, Addictive | 4 | 2018 | 317 | 0.730 |
Why?
|
| Cerebral Cortex | 4 | 2017 | 415 | 0.730 |
Why?
|
| Tobacco Products | 4 | 2022 | 234 | 0.720 |
Why?
|
| Product Labeling | 2 | 2016 | 43 | 0.650 |
Why?
|
| Executive Function | 3 | 2019 | 106 | 0.640 |
Why?
|
| Female | 44 | 2022 | 38074 | 0.620 |
Why?
|
| Self-Assessment | 1 | 2018 | 69 | 0.610 |
Why?
|
| Male | 42 | 2021 | 37321 | 0.600 |
Why?
|
| Memory | 2 | 2009 | 214 | 0.590 |
Why?
|
| Middle Aged | 30 | 2022 | 21147 | 0.580 |
Why?
|
| Thalamus | 1 | 2017 | 82 | 0.560 |
Why?
|
| Neural Inhibition | 1 | 2017 | 80 | 0.550 |
Why?
|
| Acetylcysteine | 3 | 2022 | 296 | 0.550 |
Why?
|
| Brain | 8 | 2023 | 2176 | 0.550 |
Why?
|
| Humans | 53 | 2023 | 68618 | 0.530 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 333 | 0.500 |
Why?
|
| Drug-Seeking Behavior | 1 | 2018 | 213 | 0.500 |
Why?
|
| Neural Pathways | 2 | 2015 | 324 | 0.470 |
Why?
|
| Heart Rate | 5 | 2020 | 568 | 0.450 |
Why?
|
| Exploratory Behavior | 2 | 2014 | 79 | 0.430 |
Why?
|
| Parietal Lobe | 1 | 2012 | 59 | 0.420 |
Why?
|
| Stroop Test | 1 | 2011 | 3 | 0.400 |
Why?
|
| Electronic Nicotine Delivery Systems | 3 | 2021 | 180 | 0.390 |
Why?
|
| Cognition | 2 | 2012 | 513 | 0.380 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2010 | 2 | 0.360 |
Why?
|
| Hippocampus | 2 | 2010 | 471 | 0.350 |
Why?
|
| Dominance, Cerebral | 2 | 2010 | 65 | 0.340 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 51 | 0.330 |
Why?
|
| Nicotinic Agonists | 3 | 2014 | 111 | 0.330 |
Why?
|
| Prefrontal Cortex | 3 | 2023 | 640 | 0.330 |
Why?
|
| Temperament | 1 | 2008 | 6 | 0.320 |
Why?
|
| Ganglionic Stimulants | 2 | 2015 | 15 | 0.320 |
Why?
|
| Stress, Psychological | 3 | 2020 | 824 | 0.320 |
Why?
|
| Verbal Learning | 1 | 2008 | 29 | 0.320 |
Why?
|
| Double-Blind Method | 5 | 2016 | 1738 | 0.300 |
Why?
|
| Pilot Projects | 8 | 2021 | 1342 | 0.280 |
Why?
|
| Brain Mapping | 6 | 2015 | 532 | 0.250 |
Why?
|
| Smoking Prevention | 2 | 2017 | 259 | 0.250 |
Why?
|
| Recurrence | 4 | 2017 | 948 | 0.250 |
Why?
|
| Adolescent | 10 | 2016 | 8912 | 0.230 |
Why?
|
| Young Adult | 10 | 2017 | 5717 | 0.220 |
Why?
|
| Receptors, Nicotinic | 1 | 2022 | 41 | 0.210 |
Why?
|
| Psychotherapy, Group | 1 | 2022 | 55 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2012 | 689 | 0.190 |
Why?
|
| Treatment Outcome | 8 | 2019 | 7029 | 0.190 |
Why?
|
| Galvanic Skin Response | 1 | 2020 | 67 | 0.180 |
Why?
|
| Reaction Time | 2 | 2012 | 170 | 0.170 |
Why?
|
| Smoking Devices | 1 | 2019 | 6 | 0.170 |
Why?
|
| Self-Help Groups | 1 | 2019 | 38 | 0.170 |
Why?
|
| Photic Stimulation | 3 | 2020 | 229 | 0.170 |
Why?
|
| Administration, Cutaneous | 2 | 2009 | 56 | 0.160 |
Why?
|
| Functional Neuroimaging | 3 | 2012 | 82 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2020 | 146 | 0.150 |
Why?
|
| Association Learning | 1 | 2018 | 36 | 0.150 |
Why?
|
| Conditioning, Classical | 1 | 2018 | 57 | 0.150 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 104 | 0.150 |
Why?
|
| Task Performance and Analysis | 1 | 2018 | 150 | 0.140 |
Why?
|
| Autonomic Nervous System | 1 | 2016 | 31 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.140 |
Why?
|
| Social Support | 1 | 2019 | 423 | 0.140 |
Why?
|
| Morphine | 1 | 2016 | 76 | 0.140 |
Why?
|
| Statistics as Topic | 1 | 2017 | 219 | 0.140 |
Why?
|
| Mexico | 1 | 2016 | 38 | 0.130 |
Why?
|
| Conditioning, Operant | 1 | 2018 | 241 | 0.130 |
Why?
|
| Arousal | 3 | 2014 | 168 | 0.130 |
Why?
|
| Olfactory Cortex | 1 | 2015 | 3 | 0.130 |
Why?
|
| Awareness | 1 | 2016 | 81 | 0.130 |
Why?
|
| Synaptic Transmission | 1 | 2017 | 236 | 0.130 |
Why?
|
| Olfactory Perception | 1 | 2015 | 20 | 0.130 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 447 | 0.130 |
Why?
|
| Allostasis | 1 | 2015 | 6 | 0.130 |
Why?
|
| Learning | 1 | 2017 | 186 | 0.120 |
Why?
|
| Varenicline | 3 | 2022 | 98 | 0.120 |
Why?
|
| Evoked Potentials, Visual | 1 | 2014 | 18 | 0.120 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 79 | 0.120 |
Why?
|
| Combat Disorders | 1 | 2015 | 102 | 0.120 |
Why?
|
| Mecamylamine | 1 | 2014 | 9 | 0.120 |
Why?
|
| Self Report | 4 | 2019 | 371 | 0.120 |
Why?
|
| Nicotinic Antagonists | 1 | 2014 | 11 | 0.120 |
Why?
|
| Impulsive Behavior | 1 | 2015 | 85 | 0.120 |
Why?
|
| Quinoxalines | 1 | 2014 | 78 | 0.120 |
Why?
|
| Benzazepines | 1 | 2014 | 104 | 0.110 |
Why?
|
| Genotype | 2 | 2022 | 786 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2016 | 502 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2016 | 880 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 378 | 0.110 |
Why?
|
| Cerebrovascular Circulation | 1 | 2014 | 296 | 0.100 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2014 | 152 | 0.100 |
Why?
|
| Anxiety | 1 | 2015 | 422 | 0.100 |
Why?
|
| Mood Disorders | 1 | 2013 | 132 | 0.100 |
Why?
|
| Logistic Models | 1 | 2016 | 1420 | 0.100 |
Why?
|
| Decision Making | 1 | 2014 | 410 | 0.100 |
Why?
|
| Motivation | 1 | 2014 | 561 | 0.090 |
Why?
|
| Visual Perception | 2 | 2012 | 124 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2013 | 342 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2011 | 737 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 258 | 0.080 |
Why?
|
| Spatial Behavior | 1 | 2009 | 18 | 0.080 |
Why?
|
| Placebos | 1 | 2009 | 195 | 0.080 |
Why?
|
| Cocaine | 1 | 2014 | 555 | 0.080 |
Why?
|
| Visual Fields | 1 | 2008 | 41 | 0.080 |
Why?
|
| Personality Inventory | 1 | 2008 | 197 | 0.080 |
Why?
|
| Risk Factors | 1 | 2017 | 5731 | 0.070 |
Why?
|
| Aged | 6 | 2020 | 14862 | 0.070 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2011 | 413 | 0.070 |
Why?
|
| Random Allocation | 2 | 2020 | 442 | 0.070 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 1506 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2019 | 652 | 0.060 |
Why?
|
| Electroencephalography | 1 | 2007 | 418 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 2022 | 5 | 0.050 |
Why?
|
| Catastrophization | 1 | 2022 | 4 | 0.050 |
Why?
|
| Bupropion | 1 | 2022 | 63 | 0.050 |
Why?
|
| Rodentia | 1 | 2021 | 27 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2022 | 220 | 0.050 |
Why?
|
| Rats | 2 | 2022 | 5300 | 0.040 |
Why?
|
| Models, Animal | 1 | 2021 | 252 | 0.040 |
Why?
|
| Psychotherapeutic Processes | 1 | 2019 | 4 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2017 | 3705 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 3259 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2022 | 627 | 0.040 |
Why?
|
| Analgesia | 1 | 2019 | 58 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 123 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 352 | 0.040 |
Why?
|
| Animals | 3 | 2022 | 20881 | 0.040 |
Why?
|
| Veterans | 2 | 2015 | 904 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 1851 | 0.040 |
Why?
|
| Smokers | 1 | 2018 | 200 | 0.030 |
Why?
|
| Mental Recall | 1 | 2017 | 72 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2019 | 402 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2022 | 703 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 2800 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 260 | 0.030 |
Why?
|
| Rubber | 1 | 2015 | 13 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2015 | 67 | 0.030 |
Why?
|
| Odorants | 1 | 2015 | 52 | 0.030 |
Why?
|
| Extinction, Psychological | 1 | 2017 | 240 | 0.030 |
Why?
|
| Gray Matter | 1 | 2015 | 57 | 0.030 |
Why?
|
| Rest | 1 | 2015 | 78 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 242 | 0.030 |
Why?
|
| Individuality | 1 | 2014 | 44 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2077 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 411 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 567 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 782 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2014 | 122 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2014 | 239 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 517 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 1040 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 4655 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 951 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2012 | 328 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 621 | 0.020 |
Why?
|
| Pattern Recognition, Visual | 1 | 2010 | 69 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1593 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 2083 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2279 | 0.020 |
Why?
|
| United States | 1 | 2014 | 7367 | 0.010 |
Why?
|